Oncologist who stood up to US insurance companies lost work

BMJ 2002; 325 doi: 10.1136/bmj.325.7356.167/a (Published 20 July 2002)
Cite this as: BMJ 2002;325:167.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Wallace Sampson, editor. (wisampson@cs.com)
  1. Scientific Review of Alternative Medicine, Los Altos, CA 94022, USA

    EDITOR—From early reports of the success of high dose chemotherapy and autologous bone marrow infusion some oncologists, including me, recognised that the procedure was far from proved, dangerous, and expensive.1 I was a reviewer for several insurance companies at the time and rejected all requests for payment for both primary and metastatic disease. The companies welcomed the first few opinions, …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL